Use of Malaria Rapid Diagnostic Test to Identify *Plasmodium knowlesi* Infection

Thomas F. McCutchan, Robert C. Piper, and Michael T. Makler

Reports of human infection with *Plasmodium knowlesi*, a monkey malaria, suggest that it and other nonhuman malarial species may be an emerging health problem. We report the use of a rapid test to supplement microscopic analysis in distinguishing the 5 malaria species that infect humans.

Recent reports of *Plasmodium knowlesi* infections in humans in Sarawak and Sabah in Borneo and in the Pahang Peninsula of Malaysia have focused attention on the potential of monkey malarial parasites to be a human health issue (1,2). As much as 70% of malaria infections in regional hospitals in Borneo are the result of *P. knowlesi* infection; similar infections have been found in Thailand, the Philippines, and Singapore (3–5). To date, only patients in hospitals are being screened for the disease. To better understand the epidemiology of this apparent outbreak of *P. knowlesi* in humans, one needs a method to rapidly screen both monkeys and humans in areas of high disease prevalence, regardless of their present health status. Thus, a rapid test that could detect and distinguish among the primate malarial parasites would not only benefit individual patients but would also provide an important epidemiologic tool to monitor the overall risk and prevalence of malaria.

We have known for nearly 8 decades that, under laboratory conditions, several monkey malarial species are capable of infecting humans and that *P. knowlesi* can be transmitted to humans by mosquito bite (6,7). Work in Malaysia by a team from the National Institutes of Health nearly 50 years ago reported that transmission to humans was not occurring to any prevalent extent. Currently, we see major foci of the disease, which can be life-threatening. Although the current overall incidence of *P. knowlesi* infection in humans is low, an exacerbating problem is that it can be consistently misdiagnosed by microscopy as the more benign human malaria, *P. malariae* (1,2,8,9). The rapid replication rate of *P. knowlesi* and the resulting high level of parasitemia warrant immediate and aggressive treatment, whereas *P. malariae* does not. Although the use of PCR has been essential to defining the problem, a more rapid diagnosis would be an important tool for prompt medical treatment. Furthermore, incorporating the capability to detect *P. knowlesi* into existing rapid tests already capable of detecting the other 4 *Plasmodium* species that infect humans (*P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*) would be beneficial.

*P. knowlesi* is transmitted by members of the *Anopheles leucosphyrus* group of mosquitoes that resides in the upper canopy of the forests in large areas of Southeast Asia; these *Anopheles* mosquitoes have frequent contact with humans (10). With increasing encroachment into the forest areas to provide farmland, however, humans are likely to increase their exposure to this vector. The potential for *P. knowlesi* infection as well as other monkey malarial parasites to expand into the human population is real. While the *P. knowlesi* parasite is carried by zoophilic mosquitoes, some monkey malarial species such as *P. cynomolgi* and *P. inui* are transmitted by the same mosquito vectors that carry human malaria and therefore represent an even wider threat.

One important test developed for detecting human malarial infections is an antigen-capture test based on monoclonal antibodies (MAbs) to plasmodium lactate dehydrogenase (pLDH). The 4 human malarial LDH isoforms have been cloned, and >20 MAbs have been raised that differentially recognize epitopes among the isoforms (11,12). The specificity of a subset of these antibodies is shown in Figure 1. Of the 4 human *Plasmodium* spp., antibodies such as 17E4 and 7G9 specifically bind only to *P. falciparum* LDH, whereas antibodies such as 11D9 and 13H11 bind only to *P. vivax* LDH.

Using this panel of antibodies, we show that we can distinguish *P. knowlesi* from *P. malariae*. *P. knowlesi* binds to both the “falciparum-specific” (17E4/7G9) and the “vivax-specific” (11D9/13H11) antibodies (Figure 1, panels A and B). Furthermore, *P. knowlesi* does not react with 10D12 (an antibody specific for *P. ovale*), 7E7 (an antibody that reacts strongly with *P. malariae* and weakly with *P. falciparum*), or 9C1 (an antibody that reacts exclusively with *P. ovale* and *P. malariae*). Detecting *P. knowlesi* in monkeys, which are often co-infected with several other malaria parasites, is also important and can be achieved with the same panel of antibodies. We have tested the reactivity of the *P. falciparum*–specific antibody (17E4/7G9) with the other monkey malarial known to be indigenous to Malaysia (P. cynomolgi, P. inui, and P. field) and found that none react (Figure 1, panel C). This then serves as a basis for distinguishing *P. knowlesi* from the other prevalent forms of monkey malaria.

Author affiliations: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA (T.F. McCutchan); University of Iowa, Iowa City, Iowa, USA (R.C. Piper); and Flow Incorporated, Portland, Oregon, USA (M.T. Makler)

DOI: 10.3201/eid1411.080840
Diagnosing Plasmodium knowlesi Infection

The unexpected pattern of antibody recognition on which we based our tests led us to examine the molecular basis of recognition (Figure 2). As expected, P. knowlesi LDH is highly similar to the known pLDH isoforms. We found that only a few residue differences could account for the epitope differences detected by the 17E4/7G9 and 11D9/13H11 antibodies. We first generated a 3-dimensional model of P. knowlesi LDH and then mapped surface-exposed residues that were uniquely shared by P. falciparum or P. vivax isoforms. The protein structure was calculated

Figure 1. Binding specificity of different anti-Plasmodium lactate dehydrogenase (pLDH) antibodies. A) Shown are the reactivities of the indicated monoclonal antibodies (MAbs) to the LDH from 7 Plasmodium spp. Reactivity was determined by using an immunocapture assay as previously described (9). B) Example of an immunodipstick assay that detects P. knowlesi. An immunochromatographic strip assay containing the indicated antibodies was allowed to wick lysed blood infected with P. vivax, P. falciparum, P. knowlesi, P. ovale, or P. malariae. Blood was wicked in the presence of colloidal gold conjugated to antibody 6C9, which binds all pLDH isoforms. P. vivax LDH is immobilized only by 11D9 and 13H11, and P. falciparum LDH was only immobilized by 17E4. P. knowlesi LDH was immobilized by 11D9 and 13H11 antibodies and also by 17E4. C) An immunochromatographic strip assay containing the indicated antibodies was allowed to wick lysed blood infected with P. vivax, P. cynomolgi, P. inui, and P. knowlesi. Blood was wicked in the presence of colloidal gold conjugated to antibody 6C9, which binds all pLDH isoforms. Both P. cynomolgi and P. inui show the same epitope profile as P. vivax.

Figure 2. Modeling of the analysis of Plasmodium knowlesi lactate dehydrogenase (LDH). A) Sequence of LDH from P. knowlesi deduced from genomic DNA fragments sequenced by the Sanger malaria genome project (www.sanger.ac.uk/Projects/P_knowlesi). LDH isoforms from P. vivax, P. malariae, P. ovale, P. berghei, P. yoelli, and P. falciparum were compared with that of P. knowlesi. Residues unique to P. knowlesi and P. vivax are shown in blue; residues unique to P. knowlesi and P. falciparum are shown in red. B) Model of P. knowlesi LDH and specific epitopes. A model for P. knowlesi LDH was calculated by using WURST protein threading server (www.zbh.uni-hamburg.de/wurst/index.php) and the P. falciparum and P. vivax crystal structures (PDB: 2A94 and 2AA3). Shown is the monomer, as well as the assembled tetramer, aligned to the backbone of the P. vivax tetramer using pymol. The nicotinamide adenine dinucleotide cofactor analog 3-acetyl pyridine adenine dinucleotide is shown in black. Residues important for substrate binding and catalysis are shown in yellow. P. knowlesi residues shared only with P. vivax are shown in blue and indicate where the 11D9/13H11 epitopes could be. P. knowlesi residues shared only with P. falciparum are shown in red and indicate a critical determinant of the 17E4/7G9 epitopes.
by using the structures of *P. falciparum* and *P. vivax* LDH (PDB: 2A94 and 2AA3) and the WURST threading server (13). Here, only a few patches of residues were found to describe the *P. vivax*–specific epitope, and only 1 residue (K115) was found to describe the *P. falciparum*–specific epitope (Figure 2, panel B). Thus, the existing MAbs perform well at distinguishing pLDH isoforms despite only a small number of different surface-exposed residues.

These data show that pLDH antibodies that detect *P. falciparum* and *P. vivax* can also be used to detect and distinguish *P. knowlesi*. The 1 major caveat is that a *P. knowlesi* infection cannot be distinguished from a mixed infection with both *P. vivax* and *P. falciparum* in the blood. Mixed infections of this description, however, are infrequent, as these species do not proliferate concurrently when both are present in the blood (14,15). Furthermore, any confusion would be resolved by microscopic examination of blood that, while inadequate to distinguish *P. knowlesi* and *P. malariae*, would serve to distinguish *P. knowlesi* from mixed infections.

Obviously, an antibody specific for *P. knowlesi* would be optimal if the threat of *P. knowlesi* increases. Although development of a specific antibody would be a considerable investment, our epitope analysis discussed here indicates that only small sequence differences in pLDH isoforms are required to generate antibody panels capable of uniquely distinguishing animal pLDH isoforms.

**Acknowledgments**

We thank Brenda Rae Marshall for editorial assistance.

This work was supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.

Dr McCutchan is head of the Regulation of Growth and Development Section of the Laboratory of Malaria and Vector Research at NIAID. His work on malaria, which spans over 25 years, has resulted in the publication of >100 manuscripts on such subjects as vaccine development, parasite diagnosis, and antimalaria drug development.

**References**


Address for correspondence: Thomas F. McCutchan, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Pkwy, Rockville, MD 20892, USA; email: tmcicutchan@niaid.nih.gov

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

Search past issues of EID at www.cdc.gov/eid

1752 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 11, November 2008